Latest International Business News

Eden Innovations Ltd reports a $1.43 million half-year profit, reversing prior losses thanks to a $4.45 million property sale and significant debt reduction, while advancing international commercialisation of its concrete and fuel technologies.

Acusensus Limited reported a robust 40% increase in revenue to $40.3 million for the half-year ended December 2025, driven by new contracts and international growth. However, the company recorded a substantial $20.8 million loss, largely due to a $16 million litigation settlement and strategic investments in future growth.

Osteopore Limited has secured an exclusive three-year distribution deal with Medprin Biotech GmbH to broaden its presence in Latin America's craniofacial reconstruction market, tapping into a region poised for significant growth.

REA Group Ltd reported a solid 5% revenue increase for H1 FY26, driven by strong buyer demand and strategic AI integration, alongside announcing a $200 million on-market share buy-back.

Bio-Gene Technology Limited reports strong progress in advancing its Flavocide® and Qcide® insecticidal platforms, backed by US Department of Defense funding and key organic certification in the US.

Mayne Pharma delivered a robust FY25 performance with a 105% surge in underlying EBITDA and launched key dermatology products as it outlines a strategic growth path for FY26.

Tigers Realm Coal continues to face significant delays in selling its Russian subsidiaries due to prolonged government approval processes and challenging market conditions. The company is exploring alternative strategies as operational risks mount.

Mayne Pharma reports mixed early FY26 results with strong prescription growth in Women’s Health and improved Dermatology margins, while strategic reviews and litigation loom.

McPherson’s Limited has unveiled a sweeping two-year transformation, streamlining its brand portfolio and adopting a scalable third-party logistics model to drive growth and improve financial stability.

SPC Global Holdings delivered a transformational FY25 with robust financial results and strategic international growth, setting the stage for a confident 25% EBITDA increase in FY26.

AFT Pharmaceuticals reports a robust 33% revenue increase in the first half of FY26, driven by strong ANZ market performance and expanding international presence. The company advances its R&D pipeline and targets NZ$300 million revenue for FY27 amid strategic global expansion.

AFT Pharmaceuticals delivered a robust first half for FY26, posting 33% revenue growth and a return to profitability, driven by strong Australian sales and recovery in Asia and international markets. The company is advancing its global footprint and R&D pipeline, positioning for sustained growth.